NIH Study on Syn-One Test® as Diagnostic Tool Published in JAMA
CND Life SciencesLife Sciences, a leading medical technology company specializing in neurodiagnostic tests, has announced a groundbreaking publication in...
Jon Napitupulu
AstraZeneca Acquires Fusion to Advance Next-Gen Cancer Radioconjugates
AstraZeneca has announced a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focusing on developing next-generation...
Cybin Closes $150 Million Private Placement
Cybin Inc., a clinical-stage biopharmaceutical company focused on creating innovative psychedelic-based treatments for mental health disorders, recently completed a...
Advanced Infusion Care (AIC) Now Provides Glassia® and Aralast® NP by Takeda
AIC, a division of AIS Healthcare, has enriched its portfolio of infusion therapies by offering GLASSIA and ARALAST NP,...
JCR Pharmaceuticals Achieves Milestone with J-Brain Cargo® in Neurodegenerative Disease Research Collaboration with Alexion
JCR Pharmaceuticals Co., Ltd. (JCR), a leading specialty pharmaceutical company, has announced the achievement of a significant research milestone...
Takeda’s Iclusig® Granted FDA Approval for Newly Diagnosed Ph+ ALL
Takeda has announced that the U.S. Food and Drug Administration (FDA) has approved ICLUSIG® (ponatinib) for the treatment of...
GRAIL Unveils Innovative Risk Classification Test for Lung Cancer Study
GRAIL, LLC, a pioneering healthcare company dedicated to early cancer detection for potential curative treatment, has partnered with AstraZeneca...
BMS Strengthens Neuroscience Portfolio with Karuna Therapeutics Acquisition
Bristol Myers Squibb (BMS) has announced the completion of its acquisition of Karuna Therapeutics, Inc., marking a significant expansion...
Immunis Chairman Dr. Hans Keirstead Presents Abundance360 Moonshot
Immunis, Inc., an innovative biotech firm, announced that its Chairman, Dr. Hans Keirstead, will present at the prestigious Abundance360...
FDA Approves Breyanzi® as First CAR-T Therapy for CLL/SLL
Bristol Myers Squibb announced the accelerated FDA approval of Breyanzi® (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR)...